Sells physics-based molecular simulation software for drug and materials discovery, and develops its own drug pipeline.
Sells physics-based molecular simulation software for drug and materials discovery, and develops its own drug pipeline.
Software licences, mostly annual and sold to drug and materials researchers, are the steady line. A second line earns collaboration payments and milestones from partners using its methods, while its own drug programmes add uncertain, lumpy income.
Moat: narrow (IP / patents, process know-how, data). Decades of physics-based simulation technology create a technical edge, but the drug pipeline adds binary risk.
Headquarters: New York, New York, United States · Founded: 1990 · Employees: 850
Size Schrodinger (SDGR) is a United States Information Technology company (Packaged Software) with a market value of $2.04B, the 1760th largest of 3,085 United States companies the cockpit tracks. Shares closed at $27.20 on 18 Nov 2026.
Performance Over six months the shares gained 126.9%, against +19.6% for the median peer and -2.2% for the United States market (cap-weighted) — 2nd highest of 21 in its peer set.
Growth Revenue grew 4.8% over the last twelve months (peer median +21.1%); the operating margin is -49.6% (peer median 4.7%).
Valuation It trades at 6.6× enterprise value to sales against a peer median of 3.9× (4th most expensive of 20).
Backlog Backlog (remaining performance obligations) was $187M at 30 Sep 2026, up 251% on a year earlier — 0.7 years of trailing revenue. Backlog detail →
Short interest Short interest is 14.8% of the free float (30 Oct 2026).
Next results Next results expected around 3 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $269M | $256M | $208M | $217M | $181M |
| Revenue growth | — | +23% | -4% | +20% | — |
| Gross profit | $158M | $143M | $132M | $140M | $101M |
| EBITDA | -$128M | -$161M | -$203M | -$172M | -$142M |
| Net income | -$59.3M | -$103M | -$187M | $40.7M | -$149M |
| Free cash flow | -$117M | $12.5M | -$165M | -$2.92M | -$116M |
| Capital expenditure | $4.20M | $1.44M | $7.31M | $13.4M | $8.01M |
| Total debt | $105M | $109M | $118M | $128M | $116M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Schrodinger SDGR | $2.04B | +127% | +5% | -50% | 6.6× | n/a |
| Certara CERT | $1.71B | +139% | -4% | 4% | 4.5× | 40.1% |
| Recursion Pharmaceuticals RXRX | $1.76B | -5% | +56% | -725% | 18.8× | n/a |
| Relay Therapeutics RLAY | $3.65B | +27% | +24% | -3,095% | 273.1× | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | SDGR | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +16.2% | -2.9% | highest of 21 |
| 6-month return | +126.9% | +19.6% | 2nd highest of 21 |
| Distance from 52-week high | -20.0% | -37.3% | 7th highest of 21 |
| Revenue growth (TTM) | +4.8% | +21.1% | 4th lowest of 21 |
| Operating margin | -49.6% | 4.7% | 2nd lowest of 21 |
| EV / Sales | 6.6× | 3.9× | 4th most expensive of 20 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Schrodinger SDGR | United States | $2.04B | +127% | +5% | -50% | 6.6× | n/a | n/a |
| Pitney Bowes PBI | United States | $2.06B | -1% | -4% | 25% | 2.0× | -5.5% | -11.8% |
| Embracer EMBRAC-B.ST | Sweden | $2.06B | +36% | -14% | -42% | 1.1× | -10.8% | +12.0% |
| Shenzhen Intellifusion Technologies 688343.SS | China | $2.01B | -34% | -4% | -52% | 9.2× | n/a | n/a |
| SeeWay.ai 002405.SZ | China | $2.08B | -33% | +22% | -29% | 3.1× | n/a | n/a |
| Pine Labs PINELABS.NS | India | $2.09B | +13% | +50% | 7% | n/a | n/a | n/a |
| Shanghai Suochen Information Technology 688507.SS | China | $1.98B | +45% | +32% | -2% | 22.8× | n/a | n/a |
| Asana ASAN | United States | $2.11B | +39% | +9% | -15% | 2.4× | 8.4% | +28.4% |
| Ethos Technologies LIFE | United States | $2.12B | +63% | +112% | -16% | 2.6× | 24.8% | n/a |
| DoubleVerify DV | United States | $2.12B | +45% | +7% | 14% | 2.5× | 10.1% | +25.1% |
| Meitu 1357.HK | Hong Kong | $2.13B | -19% | +24% | 24% | 2.9× | 4.2% | +25.5% |
| Mobvista Incorporation 1860.HK | Hong Kong | $1.94B | -36% | +26% | 4% | 0.8× | -1.8% | +31.9% |
| Nayax NYAX | United States | $1.94B | -24% | +20% | 4% | 3.9× | 34.3% | +38.7% |
| Amplitude AMPL | United States | $2.15B | +160% | +20% | -25% | 5.1× | 36.7% | +27.4% |
| Justsystems 4686.T | Japan | $1.91B | +26% | +5% | 45% | 3.5× | -7.2% | +4.6% |
| Servyou Software 603171.SS | China | $2.20B | -35% | +6% | 5% | 6.4× | 34.8% | +5.9% |
| Shadowfax Technologies SHADOWFAX.NS | India | $1.88B | +58% | +69% | 10% | 4.0× | 48.1% | +43.7% |
| RAKUS 3923.T | Japan | $2.23B | +26% | +10% | 33% | 5.8× | 14.9% | +31.4% |
| UCloud Technology 688158.SS | China | $1.87B | -39% | +26% | 2% | 6.1× | n/a | n/a |
| Guangdong Aofei Data Technology 300738.SZ | China | $2.23B | -42% | +24% | 23% | 8.8× | n/a | n/a |
| Karooooo KARO | United States | $1.86B | +28% | +32% | 25% | 5.2× | 10.0% | +17.7% |
Schrodinger reported $187M of remaining performance obligations at 30 Sep 2026, up 251% from a year earlier and down 1% from the previous quarter. That is 0.7 years of trailing revenue already under contract. Book-to-bill last quarter: 0.96.